119 related articles for article (PubMed ID: 29700205)
1. Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer.
Cotogno PM; Ranasinghe LK; Ledet EM; Lewis BE; Sartor O
Oncologist; 2018 Jul; 23(7):791-797. PubMed ID: 29700205
[TBL] [Abstract][Full Text] [Related]
2. Relationship between serum markers and volume of liver metastases in castration-resistant prostate cancer.
Ranasinghe L; Cotogno P; Ledet E; Bordlee B; Degeyter K; Nguyen N; Steinberger A; Manogue C; Barata P; Lewis BE; Sartor AO
Cancer Treat Res Commun; 2019; 20():100151. PubMed ID: 31128516
[TBL] [Abstract][Full Text] [Related]
3. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Baseline ALBI Score Among Patients With Colorectal Liver Metastases: A Pooled Analysis of Two Randomized Trials.
Abdel-Rahman O
Clin Colorectal Cancer; 2019 Mar; 18(1):e61-e68. PubMed ID: 30348618
[TBL] [Abstract][Full Text] [Related]
5. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
Halabi S; Kelly WK; Ma H; Zhou H; Solomon NC; Fizazi K; Tangen CM; Rosenthal M; Petrylak DP; Hussain M; Vogelzang NJ; Thompson IM; Chi KN; de Bono J; Armstrong AJ; Eisenberger MA; Fandi A; Li S; Araujo JC; Logothetis CJ; Quinn DI; Morris MJ; Higano CS; Tannock IF; Small EJ
J Clin Oncol; 2016 May; 34(14):1652-9. PubMed ID: 26951312
[TBL] [Abstract][Full Text] [Related]
6. Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer.
Sonpavde G; Pond GR; Templeton AJ; Kwon ED; De Bono JS
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):67-71. PubMed ID: 27670718
[TBL] [Abstract][Full Text] [Related]
7. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
[TBL] [Abstract][Full Text] [Related]
8. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
[TBL] [Abstract][Full Text] [Related]
9. Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data.
Guinney J; Wang T; Laajala TD; Winner KK; Bare JC; Neto EC; Khan SA; Peddinti G; Airola A; Pahikkala T; Mirtti T; Yu T; Bot BM; Shen L; Abdallah K; Norman T; Friend S; Stolovitzky G; Soule H; Sweeney CJ; Ryan CJ; Scher HI; Sartor O; Xie Y; Aittokallio T; Zhou FL; Costello JC;
Lancet Oncol; 2017 Jan; 18(1):132-142. PubMed ID: 27864015
[TBL] [Abstract][Full Text] [Related]
10. Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker.
Heinrich D; Bruland Ø; Guise TA; Suzuki H; Sartor O
Future Oncol; 2018 Oct; 14(24):2543-2556. PubMed ID: 29925281
[TBL] [Abstract][Full Text] [Related]
11. Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer.
Szarvas T; Sevcenco S; Módos O; Keresztes D; Nyirády P; Kubik A; Romics M; Kovalszky I; Reis H; Hadaschik B; Shariat SF; Kramer G
Urol Oncol; 2018 Jun; 36(6):312.e9-312.e15. PubMed ID: 29628317
[TBL] [Abstract][Full Text] [Related]
12. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
[TBL] [Abstract][Full Text] [Related]
13. Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.
Wilkerson J; Abdallah K; Hugh-Jones C; Curt G; Rothenberg M; Simantov R; Murphy M; Morrell J; Beetsch J; Sargent DJ; Scher HI; Lebowitz P; Simon R; Stein WD; Bates SE; Fojo T
Lancet Oncol; 2017 Jan; 18(1):143-154. PubMed ID: 27979599
[TBL] [Abstract][Full Text] [Related]
14. Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.
Doctor SM; Tsao CK; Godbold JH; Galsky MD; Oh WK
Cancer; 2014 Mar; 120(6):833-9. PubMed ID: 25302607
[TBL] [Abstract][Full Text] [Related]
15. Prognostic models for predicting overall survival in metastatic castration-resistant prostate cancer: a systematic review.
Pinart M; Kunath F; Lieb V; Tsaur I; Wullich B; Schmidt S;
World J Urol; 2020 Mar; 38(3):613-635. PubMed ID: 30554274
[TBL] [Abstract][Full Text] [Related]
16. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
Rahbar K; Boegemann M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):12-19. PubMed ID: 29026946
[TBL] [Abstract][Full Text] [Related]
17. Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel.
Miyake H; Matsushita Y; Watanabe H; Tamura K; Suzuki T; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2018 Jul; 38(7):4179-4185. PubMed ID: 29970547
[TBL] [Abstract][Full Text] [Related]
18. The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population.
Heller G; Fizazi K; McCormack R; Molina A; MacLean D; Webb IJ; Saad F; de Bono JS; Scher HI
Clin Cancer Res; 2017 Apr; 23(8):1967-1973. PubMed ID: 27678453
[No Abstract] [Full Text] [Related]
19. Inflammatory markers as prognostic factors in metastatic castration-resistant prostate cancer.
Donate-Moreno MJ; Lorenzo-Sánchez MV; Díaz de Mera-Sánchez Migallón I; Herraiz-Raya L; Esper-Rueda JA; Legido-Gómez O; Rico-Marco S; Salinas-Sánchez AS
Actas Urol Esp (Engl Ed); 2020 Dec; 44(10):692-700. PubMed ID: 33010988
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.
Koo KC; Park SU; Kim KH; Rha KH; Hong SJ; Yang SC; Chung BH
Yonsei Med J; 2015 Sep; 56(5):1206-12. PubMed ID: 26256961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]